Clovis Oncology, Inc. Patent Applications Rejected
4 applications abandoned without a patent; the status gives the reason, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.
- 2021-04-15: Application 17231307; Invention IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS; Applicant Clovis Oncology, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
- 2018-10-08: Application 16154038; Invention High Dosage Strength Tablets of Rucaparib; Applicant Clovis Oncology, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
- 2016-06-15: Application 15104684; Invention Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity; Applicant Clovis Oncology, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
- 2015-10-14: Application 14784503; Invention Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor; Applicant Clovis Oncology, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
| Filed | Application | Invention | Applicant | Status | Published as | Inventor name | Inventor country | Examiner |
|---|---|---|---|---|---|---|---|---|
| 2021-04-15 | 17231307 | IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS | Clovis Oncology, Inc. Alkermes Pharma Ireland Limited | Abandoned -- Failure to Respond to an Office Action | US20210338656A1 | Jared Lopes Heather C. Losey Raymond J. Winquist Rachel Dusek Andrew David Simmons | United States United States United States United States United States | DONOGHUE, BRITTNEY ERIN |
| 2018-10-08 | 16154038 | High Dosage Strength Tablets of Rucaparib | Clovis Oncology, Inc. | Abandoned -- Failure to Respond to an Office Action | US20190099430A1 | Jeffrey Etter | United States | ANDERSON, JAMES D |
| 2016-06-15 | 15104684 | Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity | Clovis Oncology, Inc. | Abandoned -- Failure to Respond to an Office Action | US20180163271A1 | Kevin Lin | United States | WISE, OLIVIA M. |
| 2015-10-14 | 14784503 | Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor | Clovis Oncology, Inc. | Abandoned -- Failure to Respond to an Office Action | US20160074399A1 | Mei LAI Andrew Roger ALLEN | United States United States | SOLOLA, TAOFIQ A |